Rani Therapeutics Holdings, Inc. (RANI) stock
RANINasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 2/3044% above fair value
$0.53+0.00 (+0.21%)
Close on Nov 13, 2026Market cap $73.36MP/E –Yield –
Rani Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Rani Therapeutics's profit margin for the twelve months ending Sep 30, 2026 was -493.0%. For fiscal 2025 it was -1817.1%, against -2920.0% the year before.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1817.1% | +1103.0 |
| FY2024 | Dec 31, 2024 | -2920.0% | −2613.4 |
| FY2021 | Dec 31, 2021 | -306.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -452.8% | +3770.5 |
| Q2 FY2026 | Jun 30, 2026 | -432.7% | +437.6 |
| Q1 FY2026 | Mar 31, 2026 | -411.8% | −132.1 |
| Q4 FY2025 | Dec 31, 2025 | -705.3% | +35.1 |
| Q1 FY2025 | Mar 31, 2025 | -4223.3% | −1553.8 |
| Q4 FY2024 | Dec 31, 2024 | -870.3% | +3653.0 |
| Q2 FY2021 | Jun 30, 2021 | -279.7% | – |
| Q1 FY2021 | Mar 31, 2021 | -740.5% | – |
| Q3 FY2020 | Sep 30, 2020 | -2669.4% | – |
| Q2 FY2020 | Jun 30, 2020 | -4523.3% | – |
See a number that looks wrong?